Home » Topics » Regulatory » EMA

EMA
RSS

EMA issues negative opinion on delamanid for tuberculosis

July 29, 2013

EMA committee recommends approval of Revolade expanded indication

July 29, 2013

EMA's CHMP recommends approval of VEGF Trap-Eye/Eylea for new indication

July 29, 2013

EMA committee recommends Defitelio approval under exceptional circumstances

July 29, 2013

CHMP confirms Xeljanz recommendation

July 26, 2013

FDA and EMA accept Plegridy marketing applications for review

July 22, 2013

EMA grants orphan drug status to OXiGENE's Zybrestat in ovarian cancer

July 19, 2013

EMA committee recommends orphan drug status for Soliris in rare neurological disease

July 19, 2013

Oryzon obtains European orphan drug designation for ORY-1001 in AML

July 17, 2013

FDA and EMA issue decisions regarding C-Path's trial simulation tool for Alzheimer's disease

July 15, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...